Journals / Dicle Tıp Dergisi / 2019 / Cilt: 46 Sayı: 3

Anti-TNF alfa kullanan hastalarda hepatit B reaktivasyonunun değerlendirilmesi

Pages
553–557
Publication Date
2019-09-16
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Bu çalışmada anti-TNF alfa kullanan hastalarda HBV tarama oranı ve reaktivasyon sıklığının saptanması amaçlanmıştır.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Amaç: Anti-tümör nekrozis faktör alfa (anti-TNF) alfa kullanan HBsAg pozitif hastalarda profilaksi önerilmektedir.
📊
Key Findings & Data:HbsAg (-), anti-HBcIgG ( +/-) ve anti-HBsIgG (-)hastalarda ise hepatit B profilaksisi tartışmalıdır.
💡
Conclusion & Impact:Bu çalışmada anti-TNF alfa kullanan hastalarda HBV tarama oranı ve reaktivasyon sıklığının saptanması amaçlanmıştır.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Hepatit B · Anti-TNF alfa

Özet

Amaç: Anti-tümör nekrozis faktör alfa (anti-TNF) alfa kullanan HBsAg pozitif hastalarda profilaksi önerilmektedir. HbsAg (-), anti-HBcIgG ( +/-) ve anti-HBsIgG (-)hastalarda ise hepatit B profilaksisi tartışmalıdır. Bu çalışmada anti-TNF alfa kullanan hastalarda HBV tarama oranı ve reaktivasyon sıklığının saptanması amaçlanmıştır.

🔖

Cite This Article

Bozkurt, İ., Bektaş, A. (2019). Anti-TNF alfa kullanan hastalarda hepatit B reaktivasyonunun değerlendirilmesi. Dicle Tıp Dergisi, Cilt: 46 Sayı: 3, 553–557. https://doi.org/10.5798/dicletip.620594

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Aygen B, Demir AM, Gümüş M, et all. Immuno suppressive ther apyandthe risk of hepatitis B reactivation: Consensusreport. Turk J Gastroenterol. 2018; 29: 259-69.
  2. Ye H, Zhang XW, Mu R, et all. Anti-TNF therapy in patientswith HBV infection--analysis of 87 patients with in flammatory arthritis. Clin Rheumatol. 2014; 33: 119-23.
  3. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et all. Hepatitis B virus (HBV) reactivation in patients receiving tumornecrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011; 90: 359-71.
  4. Tavakolpour S, Alavian SM, Sali S. Hepatitis B Reactivation During Immuno suppressive Therapyor Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review. HepatMon. 2016; 16: e35810.
  5. Pattullo V. Prevention of Hepatitis B reactivation in thesetting of immunosuppressionClinMolHepatol. 2016; 22: 219–37.
  6. Nard FD, Todoerti M, Grosso V, et all. Risk of hepatitis B virusreactivation in rheumatoidarthritispatientsu nder going biologictreatment: Extending perspective from oldtonewerdrugs. World J Hepatol. 2015; 7: 344-61.
  7. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immuno suppressivedrug therapy. Gastroenterology. 2015; 148: 215-9.
  8. Chiu YM, Lai MS, Chan KA. Commen surate in cidence and outcomes of liverenzyme elevation between anti-tumornecrosis factorusers with orwith outpriorhepatitis B virusinfections. PLoSOne. 2018; 13: e0196210.
  9. Biondo MI, Germano V, Pietrosanti M, et all. Lack of hepatitis B virus reactivation after anti-tumournecrosis factor treatment in potentialoc cultcarriers with chronic in flammatory arthropathies. Eur J Intern Med. 2014; 25: 482-84.
  10. Clarke WT, Amin SS, Papamichael K, Feuerstein JD, Cheifetz AS. Patients with core antibody positive and surfaceantigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapyhave a low rate of reactivation. ClinImmunol. 2018; 191: 59-62.
  11. Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A. Hepatitis Breactivation in psoriasispatientstreated with anti-TNF agents: prevention and management. Psoriasis (Auckl). 2017; 7: 35-40.